Search
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalLifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). … It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process.
Categories: Compounds used in a research, industrial, or household settingRosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalIt is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). … This is the subject of a clinical trial currently underway.
Categories: Drugs Used in DiabetesTromethamine
go.drugbank.com/drugs/DB03754ApprovedInvestigationalIt is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used … (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)
Categories: Compounds used in a research, industrial, or household settingMagnesium silicate
go.drugbank.com/drugs/DB13249ApprovedWithdrawnMagnesium silicate is a compound of magnesium oxide and silicon. It is the magnesium salt of silicic acid containing an unspecified amount of water. … [L2603] Under the FDA, magnesium silicate is determined as a member of the substances generally recognized as safe (GRAS) to be used as an anticaking agent.[L2605]
Mixtures: Formula ECCategories: Drugs for Acid Related DisordersCarfilzomib
go.drugbank.com/drugs/DB08889ApprovedInvestigationalCarfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. … FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Categories: P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: KYPROLIS POWDER FOR SOLUTION FOR INFUSION 60MG/VIAL, KYPROLIS POWDER FOR SOLUTION FOR INFUSION 30 MG/VIALUrea C-13
go.drugbank.com/drugs/DB09510ApprovedInvestigationalIt is currently used for the Urea Breath Test (UBT) and is available as a rapid diagnostic test (marketed as Pranactin-Citric) for the detection of Helicobacter pylori infections. … The UBT is indicated to confirm H. pylori infection and to monitor post-treatment for its eradication. Radiolabelled urea is available in two forms as 13C and 14C.
Products: Helicobacter Test Infai for Children Of The Age 3-11Butabarbital
go.drugbank.com/drugs/DB00237ApprovedIllicitWithdrawnButabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates. … [A201977,L13613] This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety.
Vonoprazan
go.drugbank.com/drugs/DB11739ApprovedInvestigational[A253702] In May 2022, the FDA approved the use of vonoprazan in a co-packaged product containing amoxicillin and clarithromycin for the treatment of _H. pylori_ infection. … PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders.
Synonyms: 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamineCategories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Zenocutuzumab
go.drugbank.com/drugs/DB15559ApprovedInvestigational[L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma. … [A264833] On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab for the treatment of non-small cell lung cancer and pancreatic adenocarcinoma.
Darolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigationalDarolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). … This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists.